Atopic Dermatitis: Global Market Growth, Trends, Opportunities & Outlook 2019-2024 -

DUBLIN--()--The "Atopic Dermatitis Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

Food allergy has been essentially highly debatable for decades in atopic dermatitis, with some common food, including milk, egg, and soy. There is a lot of literature which provides evidence that common food exacerbate atopic dermatitis.

The malfunction in the immune system of the human body due to asthma is also among the major causes for atopic dermatitis. In addition, skin irritants also occur because of certain soaps, detergents, perfumes etc. Thus, the allergic reactions particularly due to food is one major factor increasing the burden of atopic dermatitis and driving this market.

Other factors driving this market is the rich pipeline portfolio with products in advanced stages of clinical development, increasing government funds to support research for this disease, and rising campaigns to raise eczema awareness.

Corticosteroids Dominated the Overall Market, by Drug Class

Corticosteroids are referred to as cortisone-like medicines that are used as pain relief medication for inflammation in the body. These drugs are known to have effects, such as reduced itching, swelling, allergic reactions, and redness. In addition, these drugs are use as the first line treatment for different diseases, such as skin problems, severe allergies, arthritis, and asthma. Around 30 corticosteriod compounds have been licensed for atopic dermatitis treatment of which Hydrocortisone is considered to be the first.

The rising innovations have led to the advent of counterfeit medicines and alternative drugs such as immuno-modulators pimecrolimus, and tacrolimus. However, these alternatives have pitfalls, such as selective effectiveness and high cost. Hence, topical corticosteroids play a vital role in the atopic dermatitis treatment.

North America Captured the Largest Market Share, and is Expected to Retain Its Dominance

North America is expected to provide high business for the atopic dermatitis market, over the forecast period, 2019-2024. The factors, such as high treatment awareness among the patient population across the United States and Canada, healthcare infrastructure, early adoption of novel medications, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets help the lucrative nature of this market in North America.

Though both countries deal with heavy healthcare expenditure, there are an increasing number of campaigns organized each year by certain foundations, such as the PAN Foundation, National Eczema Associations, and pharmaceutical companies along with grants.

Competitive Landscape

The presence of major market players, such as Pfizer, F Hoffmann-La Roche, Allergan, Novartis, and Bayer AG, is increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies. They are also collaborating with successful personalities, initiatives, or programs at the national levels, which promote their product, and are, thus, recognized earlier than other brands in the market.

Key Topics Covered





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Burden of Allergic Reactions with Major Role of Food Allergy

4.2.2 Growing Government Expenditure Regarding Atopic Dermatitis

4.2.3 Increasing Campaigns to Raise Atopic Dermatitis Awareness

4.3 Market Restraints

4.3.1 Costs Variations of Treatments Limits Patient Access

4.3.2 Serious Adverse Effects Related to Certain Therapeutic Drugs

4.4 Porter's Five Forces Analysis


5.1 By Drug Class

5.1.1 Corticosteroids

5.1.2 Emollients/Moisturizers

5.1.3 IL-4 & PDE4 Inhibitors

5.1.4 Calcineurin inhibitors

5.1.5 Antibiotics

5.1.6 Other Drug Classes

5.2 By Administration Type

5.2.1 Topical

5.2.2 Oral

5.2.3 Injectable

5.3 Prescription Type

5.3.1 Over-the-counter (OTC)

5.3.2 Prescription

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle East & Africa

5.4.5 South America


6.1 Company Profiles

6.1.1 Abbvie Inc.

6.1.2 Allergan PLC

6.1.3 Bausch Health Companies Inc.

6.1.4 GlaxoSmithKline PLC

6.1.5 Encore Dermatology Inc.

6.1.6 Nestle

6.1.7 LEO Pharma A/S

6.1.8 Novartis International AG

6.1.9 Pfizer Inc.

6.1.10 Regeneron Pharmaceuticals Inc.


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatology

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatology